RecruitingPhase 4NCT05440240

Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture

Percutaneous Needle Fasciotomy (PNF) +/- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial

Sponsor

Regionshospitalet Silkeborg

Enrollment

400 participants

Start Date

Jan 10, 2023

Study Type

INTERVENTIONAL

Conditions

Neoplasms Musculoskeletal Diseases Neoplasms by Histologic Type Connective Tissue Diseases Neoplasms, Connective and Soft Tissue Neoplasms, Connective Tissue Joint Diseases Dupuytren Contracture Fibroma Neoplasm, Fibrous Tissue Dupuytren's disease contracture

Summary

Comparing percutaneous needle fasciotomy +/- corticosteroid injection for Dupuytren's contracture affecting metacarpophalangeal joints. A clinician-initiated, multicenter, randomized controlled trial.

Eligibility

Min Age: 45 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Corticosteroid injection, a procedure called Percutaneous needle fasciotomy, and others for people with connective tissue diseases, dupuytren contracture, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 45 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREPercutaneous needle fasciotomy

Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre

DRUGCorticosteroid injection

Depo-Medrol

OTHERSaline injection

Isotonic saline

Locations(1)

Silkeborg Regional Hospital

Silkeborg, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05440240

Related Trials

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796209 locations

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT0721360922 locations